Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Evogene Price Performance

NASDAQ:EVGN opened at $1.90 on Friday. The firm has a market capitalization of $10.19 million, a P/E ratio of -0.43 and a beta of 1.30. The company’s fifty day moving average price is $1.70 and its 200-day moving average price is $3.29. Evogene has a 1-year low of $1.20 and a 1-year high of $10.40.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.